From the publishers of The New England Journal of Medicine

Save time and stay informed. Our physician-editors offer you clinical perspectives on key research and news.

  1. Home>
  2. Specialties>
  3. General Medicine>
  4. Summary and Comment

Low Doses of Intradermal Flu Vaccine Perform Well

Intradermal flu vaccine could prove to be useful in the event of future shortages.

Because the skin contains large numbers of antigen-presenting cells, intradermal vaccination often elicits antibody response more efficiently than does intramuscular vaccination. In two open-label, industry-sponsored studies, researchers explored serologic responses to low doses of intradermal influenza vaccine.

One research group randomized 100 healthy young adults to receive either the standard IM dose of the 2003-2004 trivalent influenza vaccine, or 20% of the standard dose administered intradermally. Although titers to individual vaccine components varied somewhat by administration route, seroconversion and seroprotection rates at 3 weeks after vaccination were similar in the two groups.

Another group randomized 238 healthy adults (45% older than 60) to receive either the standard IM dose of the 2003-2004 flu vaccine, or an intradermal dose of the vaccine, slightly reconfigured to 40% of standard composition. Subjects who were younger than 60 had similar responses to both routes. Among the older group, responses were less vigorous overall, and, for one antigen, response to intradermal vaccination was significantly less than response to intramuscular vaccination. Still, seroprotection rates exceeded 90% against all antigens in both age groups.

Local reactions to intradermal vaccination were common but short-lived in both studies.

Comment: Although the findings need clinical confirmation, these studies join others in suggesting that intradermal administration of the flu vaccine could stretch a limited supply -- a useful take-home message in the event of future shortages. Editorialists also note that exploiting the immune potency of the dermis could enhance vaccine immunogenicity in populations in which the efficacy of IM vaccination has been disappointing (e.g., elders).

— Abigail Zuger, MD

Published in Journal Watch General Medicine December 14, 2004

Citation(s):

Kenney RT et al. Dose sparing with intradermal injection of influenza vaccine. N Engl J Med 2004 Nov 25; 351:2295-301.

Belshe RB et al. Serum antibody responses after intradermal vaccination against influenza. N Engl J Med 2004 Nov 25; 351:2286-94.

La Montagne JR and Fauci AS. Intradermal influenza vaccination -- Can less be more? N Engl J Med 2004 Nov 25; 351:2330-2.

Your Remark:

Reader Remarks are intended to encourage lively discussion of clinical topics with your peers in the medical community. Please consider this when composing your remark.

Fields marked with an * are required.

Name as you'd like it to appear:

Submitting a comment indicates you have read and agreed to the remark guidelines and declare:*

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

 

CLEAR erases anything you've added in any part of the form. CONTINUE allows you to check your entire post (and edit it if necessary) before submitting.

To ensure that your Reader Remark is not formatted as one long paragraph, precede new paragraphs with either a blank line or an indentation.

Search

Advanced

Article Tools

Reader Remarks

Sign-In

Forgot your password?

New to Journal Watch?

E-mail Alerts

Delivered to your inbox.
Tailored to your interests. Free.

Sign Up Now!

Journal Watch Newsletters

Available in 13 specialties with convenient delivery and 10 free online CME exams.

Subscribe Now!

Copyright © 2004. Massachusetts Medical Society. All rights reserved.